Phase I/II Study of Autologous (Central Memory/Naïve) CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T Cell Receptor for Treatment of AML

This phase I/II trial studies the side effects of laboratory-treated (central memory/naive) cluster of differentiation 8+ T cells (autologous Wilms tumor [WT]1-T cell receptor [TCRc]4 gene-transduced CD8-positive central memory T-cells [TCM]/naive T cells [TN] lymphocytes) and how well it works in treating patients with acute myeloid leukemia that is newly diagnosed or has come back. Genetically modified therapies, such as autologous WT1-TCRc4 gene-transduced CD8-positive TCM/TN lymphocytes, are taken from a patient's blood, modified in the laboratory so they specifically may kill cancer cells with a protein called WT1, and safely given back to the patient. The "genetically modified" T-cells have genes added in the laboratory to allow them to recognize leukemia cells that express WT1 and kill them.

开始日期2017-11-06

申办/合作机构

Fred Hutchinson Cancer Center

[+1]

NCT02408016 / Terminated临床1/2期

Phase I/II Study in WT1-Expressing Non-small Cell Lung Cancer and Mesothelioma, Comparing Cellular Adoptive Immunotherapy With Polyclonal Autologous Central Memory to Naïve CD8+ T Cells That Have Been Transduced to Express a WT1-Specific T-Cell Receptor

This phase I/II trial studies the side effects and best dose of genetically modified T cells in treating patients with stage III-IV non-small cell lung cancer (NSCLC) or mesothelioma. Many types of cancer cells, including NSCLC and mesothelioma, but not most normal cells, have a protein called Wilms tumor (WT)1 on their surfaces. This study takes a type of immune cell from patients, called T cells, and modifies their genes in the laboratory so that they are programmed to find cells with WT1 and kill them. The T cells are then given back to the patient. Cyclophosphamide and aldesleukin may also stimulate the immune system to attack cancer cells. Giving cyclophosphamide and aldesleukin with laboratory-treated T cells may help the body build an immune response to kill tumor cells.

开始日期2015-05-22

申办/合作机构

Fred Hutchinson Cancer Center

[+1]

100 项与 Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes(National Cancer Institute) 相关的临床结果

登录后查看更多信息

100 项与 Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes(National Cancer Institute) 相关的专利（医药）

登录后查看更多信息

100 项与 Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes(National Cancer Institute) 相关的药物交易

登录后查看更多信息

研发状态

适应症	最高研发状态	国家/地区	公司
间皮瘤	终止	美国更多	National Cancer Institute 更多
非小细胞肺癌	终止	美国更多	National Cancer Institute 更多

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02770820 (CTgov)	临床1/2期	复发性急性髓细胞白血病 \| 肾母细胞瘤一线 NCCN 2016 Intermediate Risk AML \| NCCN 2016 Poor Risk AML \| HLA-A*02:01 Positive	9	Laboratory Biomarker Analysis+Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes+Aldesleukin	(獵艱襯繭範餘鏇衊範膚) = 憲網鹹積鬱膚艱廠積鑰窪齋鑰窪願艱範鑰壓壓 (觸繭製艱餘積廠廠艱鹽, 築築觸簾觸鑰遞觸顧鏇 ~ 夢鑰蓋憲簾淵製壓選鑰) 更多	-	2021-06-23
NCT02408016 (CTgov)	临床1/2期	转移性非小细胞肺癌 \| 非小细胞肺癌IIIB期 \| 恶性胸膜间皮瘤 \| 非小细胞肺癌IIIA期 \| 非小细胞肺癌 III期 \| 复发性非小细胞肺癌 \| 肾母细胞瘤	11	Laboratory Biomarker Analysis+Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes+Cyclophosphamide+Aldesleukin (Arm I, Stage I (T Lymphocytes, Cyclophosphamide, IL-2))	(製鬱蓋鹹簾選鑰糧蓋願) = 築淵構鏇蓋鹹衊鏇淵餘蓋醖夢廠糧襯繭鬱齋廠 (鹹憲憲鹽糧壓齋獵鑰餘, 觸獵顧選積選鹽繭繭獵 ~ 糧鑰襯鏇蓋窪築願築醖) 更多	-	2021-09-13
NCT02408016 (CTgov)	临床1/2期		11	Laboratory Biomarker Analysis+Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes+Cyclophosphamide+Aldesleukin (Arm I, Stage II (T Lymphocytes, Cyclophosphamide, IL-2))	(製鬱蓋鹹簾選鑰糧蓋願) = 齋鏇壓壓鹹鑰網廠壓鏇蓋醖夢廠糧襯繭鬱齋廠 (鹹憲憲鹽糧壓齋獵鑰餘, 構範顧願簾繭構壓衊壓 ~ 積獵網簾製顧夢願製夢) 更多	-	2021-09-13